Post by Teva Pharmaceuticals

Vitiligo can affect far more than the skin. This chronic autoimmune disease, which causes loss of pigmentation, often carries a significant impact on a person’s quality of life, self-image, and daily social interactions. And despite recent advances, treatment options remain limited. Today, we announced plans to advance TEV-’408, our investigational human monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo. “TEV-’408 exemplifies the type of innovative, Teva-discovered program we are prioritizing as we continue to advance and strengthen our immunology pipeline,” said Richard Francis, President and Chief Executive Officer of Teva. “Grounded in compelling biology and focused on meaningful unmet need, TEV-’408 reflects our progress in our Pivot to Growth strategy and our commitment to pursuing differentiated innovation for patients.” To learn more, join the webcast today at 8:00 AM EST: https://lnkd.in/e5ZZYY3T Read the full press release: https://bit.ly/4ynYagW